Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

Launched by AFFILIATED CANCER HOSPITAL & INSTITUTE OF GUANGZHOU MEDICAL UNIVERSITY · May 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how to better predict and manage a painful condition called acute radiation-induced oral mucositis (RIOM) in patients with nasopharyngeal carcinoma, which is a type of cancer located in the area behind the nose. The goal is to find effective ways to identify patients at high risk for developing severe mouth sores due to their radiation treatment, helping dentists and doctors to create better care plans. By analyzing specific factors and using advanced prediction models, researchers hope to reduce the chances of patients experiencing severe oral complications during their treatment.

To participate in this trial, patients should be diagnosed with nasopharyngeal carcinoma at an early to moderate stage, be starting radiation therapy for the first time, and have no ongoing oral diseases that need treatment. Participants can expect to be closely monitored throughout their radiation therapy, and their experiences will help improve future care for others facing similar challenges. The study is currently recruiting participants aged 18 and older, and it's important that those interested can commit to completing the treatment as planned.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Confirmed as nasopharyngeal carcinoma through pathological tissue biopsy, AJCC 8th edition bed staging is I-Iva stage, with no distant metastasis
• • First time receiving radical radiation therapy and receiving RTOM observation and treatment throughout the entire process in the Department of Stomatology
• • Complete information on anti-tumor treatment materials
• • No oral mucosal diseases that have not been effectively controlled in the past or still require long-term medication treatment
• • Other diseases that do not affect the treatment of nasopharyngeal carcinoma
• Exclusion Criteria:
• • Failure to complete radiotherapy, or material release time delayed by more than two weeks compared to plan
• • There are other diseases that affect the examination and treatment of oral mucosal inflammation, such as restricted mouth opening, Schegren's syndrome, etc
• • Expected survival time less than 6 months
• • Cases where patients withdraw from clinical trials at any time and for any reason